Source comparison
Chronic Tendinopathy versus Acute Repair: Model-Guided Selection
The two agents show different utility depending on the tendinopathy stage being modelled: For acute tendon laceration/rupture repair (primary surgery model — rat Achilles complete transection + repair): TB-500’s tenocyte migration and VEGF-driven vascular recr
This comparison does not assign a generated winner or score.
- The two agents show different utility depending on the tendinopathy stage being modelled:
- For acute tendon laceration/rupture repair (primary surgery model — rat Achilles complete transection + repair): TB-500’s tenocyte migration and VEGF-driven vascular recruitment are dominant early-phase benefits. TB-500 produces superior cell density and neovascularisation in the 0–14 day window, accelerating the proliferative phase. GHK-Cu’s TIMP/MMP anti-degradation and Nrf2 antioxidant biology become more relevant in the subsequent remodelling phase (day 14–42).
- For chronic tendinopathy (repetitive loading model — rat wheel-running overuse, 8 weeks): GHK-Cu’s ability to modulate the aberrant MMP activity and oxidative biology of chronic tendinopathy without driving neovascularisation is mechanistically preferred. In overuse tendinopathy, excessive neovascularisation (neo-vessel ingrowth) is a pathological feature — TB-500’s VEGF-A upregulation requires monitoring in this context. GHK-Cu +22–28% TIMP-1 and −22–28% MMP-1 in the chronic setting moderates the catabolic excess without adding angiogenic biology.